Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Incara Pharmaceuticals (NasdaqNM:INCR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
79 T.W. Alexander Drive
4401 Research Commons
Research Triangle Pa, NC 27709
Phone: (919) 558-8688
Fax: (919) 558-8686
Email: info@incara.com
Employees (last reported count): 21
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 46%
·Over the last 6 months:
 · 2 insider sells; 8,000  shares
  (0.2% of insider shares)
·Institutional: 0% (0% of float)
(7 institutions)
·Net Inst. Buying: 4,000  shares (+49.86%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Incara Pharmaceuticals Corporation develops innovative pharmaceutical products and treatments for major diseases afflicting large patient populations. The Company is currently developing a diversified portfolio of three potentially breakthrough treatments. Each of these products targets a medical disorder for which there are no fully effective treatments. These three products are as follows: OP2000, an ultra-low molecular weight heparin; liver precursor cell transplant, as a treatment for liver failure; and small molecule catalytic antioxidants, as a treatment for stroke and heart attack. The Company generally plans to enter into relationships with companies that have manufacturing, sales or marketing capabilities to bring its products to market.
More from Market Guide: Expanded Business Description

Financial Summary
Incara pharmaceuticals is engaged in development of pharmaceutical products for treatment of: inflammatory bowel disease, liver disorders and novel small molecule antioxidants for disorders such as stroke, asthma and reperfusion injury. For the nine months ended 6/30/01, revenues fell 82% to $18 thousand. Net loss applicable to Common totaled $13.1 million, up from $4.5 million. Results reflect the absence of contract revenues and the recognition of a $6 million loss incurred by Incara Development.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Clayton Duncan, 51
Chairman, Pres, CEO
$355K$233K
Richard Reichow, 50
Exec. VP, CFO, Treasurer and Sec.
287K93K
David Ward, M.D., 54
Exec. VP, R&D
287K--  
W. Bennett Love, 45
VP, Corp. Planning/Communications
146K--  
John Richert, 50
VP, Market Devel.
142K--  
Dollar amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:INCRAs of 31-Aug-2001
Price and Volume
52-Week Low
on 9-Apr-2001
$1.00 
Recent Price$1.45 
52-Week High
on 6-Sep-2000
$4.50 
Beta2.27 
Daily Volume (3-month avg)15.6K
Daily Volume (10-day avg)19.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-58.6%
52-Week Change
relative to S&P500
-44.4%
Share-Related Items
Market Capitalization$12.2M
Shares Outstanding8.38M
Float4.50M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.27 
Earnings (ttm)-$1.93 
Earnings (mrq)-$0.41 
Sales (ttm)$0.00 
Cash (mrq)$0.23 
Valuation Ratios
Price/Book (mrq)5.46 
Price/EarningsN/A 
Price/Sales (ttm)620.76 
Income Statements
Sales (ttm)$18.0K
EBITDA (ttm)-$9.51M
Income available to common (ttm)-$15.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsSep 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-224.63%
Return on Equity (ttm)-336.19%
Financial Strength
Current Ratio (mrq)1.47 
Debt/Equity (mrq)0.02 
Total Cash (mrq)$1.95M
Short Interest
As of 8-Aug-2001
Shares Short4,000 
Percent of Float0.1%
Shares Short
(Prior Month)
0 
Short Ratio0.14 
Daily Volume29.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.